Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Nat Commun · 2026 · PMC12992618 · PMID 41654519

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the difference between the combination and exarafenib monotherapy did not reach statistical significance in the CTG-3703 model, a trend towards enhanced efficacy was also observed (Fig. 6e , middle).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.